Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes (Follow-AYA)

In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility potential, including success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex. Recent treatment regimens have continuously implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.

It is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function/fertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questions is highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of the quality of life in young cancer survivors.

The study therefore aim to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian/testicular dysfunction and/or fertility impairment and premature ovarian insufficiency/oligo/azoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation/fertility treatment and patients' satisfaction related to these procedures in Europe shall be analysed to support patient-centric care.

Reproductive health counselling should not be restricted to evaluating the individual risk of gonadotoxicty and offering fertility preservation to those at risk. It also includes the sexual health, the use of post-cancer treatment contraception for those recommended to delay attempting pregnancy after a cancer diagnosis and the identification of potential obstetrical and neonatal risks to provide individualized, risk-adapted follow-up during pregnancy. An increased risk of obstetrical and neonatal complications has been reported for several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes. Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of cancer treatment received (e.g pelvic irradiation, anthracycline, targeted therapy, immunotherapy…), all of which may influence the outcomes.

The main objectives of this retrospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:

• To establish harmonized databases with clinical data on pre- and post-cancer therapy and reproductive outcomes in AYA patients followed longitudinally.

• To evaluate the impact of cancer treatment on long-term fertility according to cancer type and individual patients' characteristics (pre- and post-treatment) in male and female AYA populations.

• To evaluate effect of cancer therapies on ovarian function in female AYA patients

• To evaluate long-term effect on the endocrine function of the testis in male AYA patients i.e., the frequency of hypogonadism.

• To evaluate the obstetrical and neonatal outcomes according to the disease and treatment.

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer; Infertility; Male Fertility; Late Effects; AYA Cancer Survivors; Female Fertility

Detailed Description

Fertility preservation (FP) and fertility counselling at the time of diagnosis and throughout follow-up are recommended to improve the quality of life of young patients diagnosed with cancer (Lambertini et al. 2020; Su et al.2025). Indeed, it has been shown that gonadal function, as well as fertility capacity after treatment are crucial aspects for AYA cancer survivors (Letourneau et al.2012). While natural conception can be possible after cancer treatment, cancer-treatment related risk factors for impaired fertility, including a drastically reduced reproductive window, have been identified.

FP techniques are progressing rapidly and have demonstrated their effectiveness in terms of pregnancy chances and live-birth rates. However, it remains difficult to establish firm and evidence-based FP strategies according to a patient's individual factors and cancer treatment. In addition, it remains crucial to carefully balance the risk-benefit of FP procedures and the potential of ovarian/fertility impairment, to examine the efficiency and safety of FP procedures and pregnancies as well as to assess patients' satisfaction regarding FP procedures. Large scale prospective and systematic short- and long-term data on the impact of specific cancer therapies on fertility based on fertility parameters such as ovarian reserve markers, sperm quality and pregnancies hardly exist. Specialized centres and joint regional and national network initiatives have started collecting such data. However, even though these initiatives are of great value and are sufficient to generate data from common cancer diseases such as breast or testicular cancer, rare cancers as well as on novel therapeutics (e.g. anti VEGF or immune therapies) and more complex cancer treatment regimen require large scale data collection initiatives to gain in-depth robust data for appropriate individual fertility-related counselling of female and male AYA patients.

In female cancer patients, it has been shown that serum AMH levels variations may be a direct and real-time indicator of follicular depletion and recovery during and after cancer treatment, as well as it is a non-invasive and reproducible marker (Anderson et al., 2022; Decanter et al., 2021). Systematic follow-up of AMH has been suggested in AYA patients with at least a measurement at baseline and within the 2 years following the end of gonadotoxic treatment (Su et al., 2025; Decanter et al., 2024; von Wolff et al. 2025). In parallel, menstrual function pattern should be regularly analysed as a relevant clinical surrogate and independent variable to determine prevalence of cancer treatment-induced amenorrhea, it's duration and hormonal and clinical signs of potential post treatment premature ovarian insufficiency (POI).

In the FollowAYA study within the PredictAYA project, the investigators therefore aim to set up a large-scale network structure of previously established data collection programmes in specialized centres/networks to evaluate the ovarian toxicity, the prevalence of impaired ovarian function, it's course and/or fertility impairment and POI following specific treatments, identification of predictive markers. Additionally, data on the use of FP and/or subsequent use of artificial reproductive treatment (ART) as well as patients' satisfaction related to these procedures in Europe shall drive the understanding of patient-centric care.

In male cancer patients, the long-term reproductive and endocrine effects of cancer treatment on testicular function remain poorly studied, with existing data based on small cohorts and incomplete clinical characterization. No validated pre-conceptional tests currently exist to guide patients in deciding between natural conception and the use of cryopreserved sperm. Because treatment regimens vary widely even within the same cancer type and incidence rates are relatively low, only a coordinated European effort can generate sufficiently robust data. PredictAYA addresses this need by establishing a harmonized data platform across large male AYA cohorts. Its goals are to develop personalized risk-prediction tools for reproductive and testicular endocrine outcomes, provide evidence-based counselling on FP and future options, and design standardized follow-up protocols enabling early diagnosis and treatment of hypogonadism and infertility. As only limited evidence on sperm DNA damage and epigenetic alterations exist, these aspects will be validated in selected sub-cohorts to assess the frequency and persistence of chemotherapy-induced dysfunction (Farnetani et al. 2023 and 2024, Chan et al. 2023).

Safety of pregnancy should also be an issue in counselling. Information on potential obstetrical and neonatal risks should also be given to provide individualized, risk-adapted follow-up during pregnancy. There is evidence that pregnancy in cancer survivors does not increase the risk for recurrence in women who became pregnant compared to those who did not, particularly in breast cancer (Lambertini et al. 2020). However, data remain limited regarding the impact of pregnancy timing, method of conception and the influence of adjuvant therapy such as hormonotherapy and immunotherapy (Bussies et al. 2022) Counselling patients in this context is particularly complex due to the lack of comprehensive human data (Maggen et al. 2021; Borgers et al. 2021). Finally, approximately 25-27 in 100,000 pregnancies is complicated by cancer, leaving specialists and patients to deal with a complex oncologic-obstetric decision-making process (Boere et al., 2021). PredictAYA also aim to confront the cancer recurrence rates during the follow up in haematological patients who were pregnant while receiving treatment for cancer versus expected recurrence rates for those neoplasms.

An increased risk of neonatal and obstetrical complications has been reported in several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes (Shliakhtsitsava et al. 2018, van der Kooi et al. 2019, van der Kooi et al. 2021), although population-based studies are reassuring regarding the health-related quality of life and the risk of congenital anomalies in the offspring in cancer survivors (Balcerek et al., 2021, Winther et al., 2004). Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of treatment (e.g. pelvic irradiation, anthracycline, targeted therapy), all of which may influence the outcomes (Hartnett et al., 2018, Sunguc et al., 2024). To provide evidence-based guidance of pregnancies in women with a history of cancer, the current body of research is insufficient and warrants further investigation.

Moreover, previous population-based studies reported a significantly lower childbirth rate in patients with aggressive tumours, with an increasing number of patients who used ART (Entrop et al., 2023a, Entrop et al., 2023b). ART has been associated with specific maternal and neonatal outcomes in infertile patients, related to placentation and endocrine environment (Bosdou et al., 2020, Busnelli et al., 2024). However, the impact of the conception methods, including ART after treatment and use of cryopreserved materials, on obstetrical and neonatal outcomes in cancer survivors' population is almost unknown (Borgmann-Staudt et al., 2022). Finally, few studies reported similar rate of unplanned pregnancies after cancer treatment and revealed a lack of contraception counselling in this population (Quinn et al. 2014, Massarotti et al 2021).

• Study Type: Observational
• Enrollment (Estimated): 4000

Contacts and Locations

• Study Contact: Name: Kenny A Rodriguez-Wallberg, Professor, MD; Phone Number: +46852481213; Email: kenny.rodriguez-wallberg@ki.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

AYA cancer patients aged 15-39 at diagnosis and treated for their disease at any of the participating study centers

Description

Inclusion Criteria:

• Female and male cancer patients aged between 15 and 39 years at diagnosis.
• First diagnosed with any cancer disease between 01/01/2000 and 31/12/2025
• Treated with chemotherapy and/or targeted therapy/immunotherapy and/or radiotherapy/ radioactive iodine therapy and/or testis/scrotal or gynaecological surgery.
• Information on treatment received available.

Exclusion Criteria:

• Pre-existing known POI at cancer diagnosis
• Cancer treated by surgery alone (except gynaecological/testicular surgery)
• Data from second malignant neoplasm diagnose and treatment
• Adult subject of a measure of legal protection and/or patients with serious mental disorders

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
Sub-cohort A: Gonadal function in females
Sub-cohort B: Gonadal function in males
Sub-cohort C: Survival and pregnancy outcomes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Constitution of the RedCap database	Constitution of a centralized RedCap database based on the collected variables from 4000 individuals diagnosed with cancer at age 15-39.	June 2030
Treatment impact on AMH (1)	Percentage of included patients in which AMH decreases to below detection limit and percentage of AMH decrease if AMH stays above detection limit.	June 2030
Incidence of azoo/oligo/normozoospermia	Incidence of azoo/oligo/normozoospermia through the analysis of sperm parameters pre/post treatment	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of disease (1)	Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of disease	June 2030
Treatment impact on AMH (2)	Change of menses pattern pre/post treatment.	June 2030
Treatment impact on AMH (3)	Prevalence of POI post treatment.	June 2030
Treatment impact on AMH (4)	Role of individual genetic backgrounds in menstrual function abnormalities and ultra-low or undetectable AMH levels.	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of disease (2)	Influence of disease type and stage on the obstetrical outcomes.	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of disease (3)	Influence of disease type and stage on the neonatal outcomes.	June 2030

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and type of FP according to the type of cancer and treatments.		June 2030
Safety of FP procedures (1).	Short-term clinical safety of FP procedures.	June 2030
ART induced pregnancy (1)	Cumulative incidence of spontaneous or ART induced pregnancy.	June 2030
Incidence of overt and compensated hypogonadism	Incidence of overt and compensated hypogonadism pre/post treatment according to the type of cancer treatment .	June 2030
Correlation between hormonal values/routine sperm parameters and clinical characteristics	Correlate hormonal values/routine sperm parameters and clinical characteristics (testis volume, andrological history) at baseline with the development of azoo/oligozoospermia and/or hypogonadism post-therapy.	June 2030
Measurement of sperm DNA damage and epigenetic alterations pre and post-therapy		June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of treatment and patient characteristic (1)	Obstetrical and neonatal outcomes according to the timing of pregnancy (at diagnosis or time from remission/end of treatment to conception)	June 2030
Recurrence risk and survival after pregnancy	Recurrence (type and location) and survival rates after pregnancy according to the type of and stage of cancer disease, the cancer treatment (chemotherapy/radiotherapy/special attention to immunotherapy and targeted therapy), and the methods of conception (spontaneous versus ART).	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the method of conception	Obstetrical/neonatal outcomes in cancer survivors according to the method of conception (spontaneous or ART - type of ART and use of frozen materials).	June 2030
Prevalence of unplanned pregnancies after treatment according to the disease and patients' characteristics	Occurrence of unplanned pregnancy and associated risk (type of treatment and disease, use of contraception, patient's characteristics, time from remission/end of treatment to conception)	M60
Contraceptives use, type of contraception according to the disease, patient's characteristics and demographics	Use of contraception and associated factors (type of treatment and disease, use of contraception, patient's characteristics, time from remission/end of treatment to conception).	June 2030
Safety of FP procedures (2).	Oncologic safety of FP procedures.	June 2030
Safety of FP procedures (3).	Incidence of FP serious adverse events: OHSS, thrombosis, bleeding, infection etc.	June 2030
ART induced pregnancy (2)	Method of conception according to the type of cancer and treatments.	June 2030
ART induced pregnancy (3)	Re-use rates: ratio between number of clinical pregnancies and number of patients who asked for re-utilization.	June 2030
ART induced pregnancy (4)	Pregnancy rate after reuse of cryopreserved gametes and/or ovarian tissue defined by the ratio between the number of clinical pregnancies and number of ART attempts.	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of treatment and patient characteristic (2)	Obstetrical and neonatal outcomes according to the type of treatment (chemotherapy/radiotherapy/special attention to immunotherapy and targeted therapy)	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of treatment and patient characteristic (3)	Obstetrical and neonatal outcomes according to the mothers condition (previous disease, age, co-morbidities)	June 2030
Prevalence of pregnancy, obstetrical and neonatal outcomes according to the type of treatment and patient characteristics (4)	Obstetrical and neonatal outcomes according to the presence of cancer genetic predisposition (Lynch, P53 mutation, BRCA and others).	June 2030

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Collaborators: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; University of Leeds; Linkoeping University; University of Leipzig; University of Edinburgh; The Netherlands Cancer Institute; University of Florence; Region Stockholm; European Commission; Université Libre de Bruxelles; Ospedale Policlinico San Martino; Tartu Ülikooli Kliinikum; MEDIZINISCHE UNIVERSITAT INNSBRUCK; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITATSKLINIKUM HEIDELBERG

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): July 31, 2035

Study Registration Dates

• First Submitted: May 20, 2026
• First Submitted That Met QC Criteria: May 27, 2026
• First Posted (Actual): June 3, 2026

Study Record Updates

• Last Update Posted (Actual): June 3, 2026
• Last Update Submitted That Met QC Criteria: May 27, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: cancer treatment induced late effects; infertility after cancer; AYA cancer survivours
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Neoplasms; Infertility
• Other Study ID Numbers: V1.0-17/03/2026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data from existing datasets will be centralized through the study, but rights for data sharing will limited by the scope of the ethical approvals of the respective national/regional cohorts.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No